Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSGlobeNewsWire • 06/04/26
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkGlobeNewsWire • 06/02/26
Pharming Group announces results of 2026 Annual General Meeting of ShareholdersGlobeNewsWire • 05/28/26
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersGlobeNewsWire • 05/07/26
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026GlobeNewsWire • 05/07/26
Pharming Group to report first quarter 2026 financial results and provide business update on May 7GlobeNewsWire • 04/23/26
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and olderGlobeNewsWire • 03/27/26
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and olderGlobeNewsWire • 03/24/26
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flowGlobeNewsWire • 03/12/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHARGlobeNewsWire • 03/03/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHARPRNewsWire • 02/26/26
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12GlobeNewsWire • 02/26/26
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/17/26
Why Pharming, A Top 3% Biotech Stock, Just Took A Double-Digit BeatingInvestors Business Daily • 02/02/26
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDSGlobeNewsWire • 02/01/26